Patent JPS6129733A successfully refreshed from Google Patents.
Patent US4520226A successfully refreshed from Google Patents.
US4520226A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
Assignee: HEALTH AND HUMAN SERVICES United States, Secretary of, Department of
•
Filing: 1983-01-07
•
Granted: 1985-05-28
•
Expires: 2003-01-07
Abstract
Abstract A reagent and the protocol for the treatment of Graft Versus Host Disease is disclosed. Monoclonal antibodies specific for T-lymphocytes in human donor bone marrow are covalently linked to separate ricin toxin, combined in a mixture to form a treatment reagent, and combined with bone marrow removed from a human donor. The bone marrow-reagent mixture is then infused into an irradiated recipient. This protocol virtually eliminates T-lymphocyte activity, the cause of Graft Versus Host Disease.
Inventors
- 👤 David M. Neville, Jr.
- 👤 Richard J. Youle
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:15
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
55 words
A composition for the treatment of graft versus host disease in humans consisting essentially of a mixture of equal parts of conjugate molecules TA-1:ricin, T101:ricin, and UCHT1:ricin, said conjugate molecules consisting of ricin bonded to a monoclonal antibody, TA:1, T101 and UCHT1, respectively, said monoclonal antibody having binding specificity for a thymic lymphocyte antigenic site.
Claim 2
Dependent Claim
55 words
A composition for the treatment of graft versus host disease in humans consisting essentially of a mixture of equal parts of conjugate molecules TA-1:ricin, T101:ricin, and UCHT1:ricin, said conjugate molecules consisting of ricin bonded to a monoclonal antibody, TA:1, T101 and UCHT1, respectively, said monoclonal antibody having binding specificity for a thymic lymphocyte antigenic site.
Claim 3
Independent Claim
103 words
A method for the treatment of graft versus host disease in humans consisting essentially of covalently bonding antibodies exhibiting binding specificity for human bone marrow T-cells to ricin toxin in order to form three human T-cell specific cytotoxic hybrids; mixing said three hybrids in equal parts to form a reagent; incubating in vitro said reagent with human donor bone marrow cells obtained from a human donor in the presence of lactose, washing said bone marrow cells with PBS containing 1% HA and 15 mM lactose to remove any unbound conjugates; and injecting washed bone marrow cells incubated with said reagent into irradiated recipients.
Claim 4
Independent Claim
103 words
A method for the treatment of graft versus host disease in humans consisting essentially of covalently bonding antibodies exhibiting binding specificity for human bone marrow T-cells to ricin toxin in order to form three human T-cell specific cytotoxic hybrids; mixing said three hybrids in equal parts to form a reagent; incubating in vitro said reagent with human donor bone marrow cells obtained from a human donor in the presence of lactose, washing said bone marrow cells with PBS containing 1% HA and 15 mM lactose to remove any unbound conjugates; and injecting washed bone marrow cells incubated with said reagent into irradiated recipients.
Claim 5
Dependent Claim
17 words
The method of claim 2 wherein the human T-cell specific cytotoxic hybrids are TA-1-ricin, T101-ricin, and UCHT1-ricin.
Claim 6
Dependent Claim
20 words
The method of claim 2 in which the mixture is formed by combining equal amounts of TA-1-ricin, T101-ricin, and UCHT1-ricin.
Claim 7
Independent Claim
65 words
A method for eliminating T-cells from human bone marrow grafts consisting essentially of separately convalently bonding monoclonal antibodies TA-1, T101, and UCHT1 to ricin toxins to form three human T-cell specific cytotoxic hybrids, forming a mixture by combining equal amounts of each hybrid, and incubating under standard biological conditions said mixture with human bone marrow cells in the presence of a suitable amount of lactose.
Claim 8
Independent Claim
65 words
A method for eliminating T-cells from human bone marrow grafts consisting essentially of separately convalently bonding monoclonal antibodies TA-1, T101, and UCHT1 to ricin toxins to form three human T-cell specific cytotoxic hybrids, forming a mixture by combining equal amounts of each hybrid, and incubating under standard biological conditions said mixture with human bone marrow cells in the presence of a suitable amount of lactose.
References Cited (Backward Citations)
FR63988E
Cited
US4340535A
Cited
US4359457A
Cited
US4356117A
Cited
US4397843A
Cited
US4363758A
Cited
US4368149A
Cited
US4414148A
Cited
EP0074279A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-05-27 | 1988-11-26 | 1989-05-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-05-27 | 1992-11-26 | 1993-05-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-05-27 | 1996-11-26 | 1997-05-28 | $7700.00 | Window Closed / Lapsed |